Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2.5→$2 | ― | 5.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $196→$190 | ― | 18.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55→$40 | ― | 8.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $165→$145 | ― | 14.40% | Reiterated | ||||
| Cable ONE | HOLD $448→$444 | ― | -3.70% | Reiterated | Cable ONE: Hold Rating Amid Broadband Challenges and Strategic Optimism | |||
| Lumen Technologies | HOLD $6 | ― | -3.70% | Reiterated | Lumen Technologies: Hold Rating Amid Strong Q1 Results and Macroeconomic Caution | |||
 | Arvinas Holding Company | BUY $81→$24 | ― | -0.90% | Reiterated | Analysts' Top Healthcare Picks: Arvinas Holding Company (ARVN), Alphatec Holdings (ATEC) | |||
 | Alphatec Holdings | BUY $18 | ― | -2.40% | Reiterated | Analysts' Top Healthcare Picks: Arvinas Holding Company (ARVN), Alphatec Holdings (ATEC) | |||
| Lemaitre Vascular | BUY $110 | ― | -3.30% | Reiterated | Lemaitre Vascular (LMAT) Gets a Buy from Lake Street | |||
| Trupanion | BUY $65→$60 | ― | -15.50% | Reiterated | Lake Street Keeps Their Buy Rating on Trupanion (TRUP) | |||
 | Butterfly Network | BUY $5 | ― | -18.90% | Reiterated | Lake Street Keeps Their Buy Rating on Butterfly Network (BFLY) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 9.20% | Reiterated | ||||
| Aziyo Biologics | BUY $10 | ― | -3.30% | Initiated | Aziyo Biologics (ELUT) Receives a New Rating from Lake Street | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $11 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $8 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $3.5 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $31 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $11 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $27 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $82 | ― | 4.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $925→$720 | ― | 21.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $270→$260 | ― | 14.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $265→$235 | ― | 13.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $108→$110 | ― | 7.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100→$104 | ― | 11.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $103→$95 | ― | 8.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $92→$79 | ― | 13.80% | Reiterated | ||||
| Hologic | BUY $90→$71 | ― | -11.60% | Reiterated | Hologic price target lowered to $71 from $90 at Raymond James | |||
| Graphic Packaging | BUY $30→$26 | ― | -5.90% | Reiterated | Graphic Packaging price target lowered to $26 from $30 at Raymond James | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $23→$21 | ― | 10.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 3.00% | Reiterated | ||||
 | Stryker | BUY $400→$390 | ― | -0.40% | Reiterated | Stryker (SYK) PT Lowered to $390 at Evercore ISIEvercore ISI analyst Vijay Kumar lowered the price target on Stryker (NYSE: SYK) to $390.00 (from $400.00) while maintaining a Outperform rating. | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $211 | ― | 16.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $145→$140 | ― | 8.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $48→$44 | ― | 6.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $80 | ― | 3.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $465 | ― | 7.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,020→$1,057 | ― | 3.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 3.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $48→$50 | ― | 3.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 5.90% | Reiterated | ||||
 | Block | BUY $70→$60 | ― | -2.70% | Reiterated | Buy Rating on Block: Growth Potential Amid Macroeconomic Challenges | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $360 | ― | 8.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $67 | ― | 5.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,200→$1,150 | ― | 14.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $300→$355 | ― | 12.90% | Reiterated | ||||
 | Apple | BUY $250→$270 | ― | -0.60% | Reiterated | Apple price target raised to $270 from $250 at Wedbush | |||
| Biogen | BUY $241→$187 | ― | -0.90% | Reiterated | Biogen price target lowered to $187 from $241 at H.C. Wainwright |
Rows:
